Søreide Jon Arne, Greve Ole Jacob, Gudlaugsson Einar, Størset Svein
a Department of Gastrointestinal Surgery , Stavanger University Hospital , Stavanger , Norway ;
b Department of Clinical Medicine , University of Bergen , Bergen , Norway ;
Scand J Gastroenterol. 2016;51(6):646-53. doi: 10.3109/00365521.2015.1124286. Epub 2016 Jan 5.
The term hepatoid adenocarcinoma (HAC) of the stomach was introduced three decades ago with the observation of high serum α-fetoprotein (AFP) levels in some gastric adenocarcinoma patients. This very rare gastric cancer patient subgroup is likely frequently misdiagnosed.
Two patients who were recently diagnosed with HAC of the stomach at our institution are presented. We also performed a structured literature search and reviewed pertinent articles to provide knowledge to improve the proper identification, diagnosis and management of patients with gastric HAC.
HAC is a rare subgroup of gastric carcinoma with poor prognosis. Clinical management of this population may be challenging. The scientific literature is largely based on very small patient series or case reports, and the evidence for proper decision making and management is considered weak.
All physicians involved in the diagnosis and treatment of patients with gastric cancer should pay attention to this rare subgroup to improve identification.
胃肝样腺癌（HAC）这一术语于三十年前提出，当时观察到部分胃腺癌患者血清甲胎蛋白（AFP）水平较高。这个极为罕见的胃癌患者亚组很可能经常被误诊。
本文介绍了我院近期诊断为胃HAC的两名患者。我们还进行了结构化文献检索并查阅了相关文章，以提供知识，改善胃HAC患者的正确识别、诊断和管理。
HAC是胃癌中一个预后较差的罕见亚组。该人群的临床管理可能具有挑战性。科学文献很大程度上基于非常小的患者系列或病例报告，用于正确决策和管理的证据被认为不足。
所有参与胃癌患者诊断和治疗的医生都应关注这个罕见亚组，以提高识别率。
